Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
The latest update is out from MaxCyte ( (MXCT) ).
MaxCyte announced it will release its first quarter 2025 financial results on May 7, 2025, after the U.S. market closes. The company will host a conference call to discuss these results, reflecting its ongoing efforts to maintain transparency with stakeholders and its strategic positioning in the cell therapy sector.
More about MaxCyte
MaxCyte, Inc. is a leading company in the cell-engineering industry, specializing in platform technologies that advance the discovery, development, and commercialization of next-generation cell therapeutics. Their ExPERT™ platform, based on Flow Electroporation® technology, supports the expanding cell therapy market and includes instruments, processing assemblies, and software protocols.
YTD Price Performance: -39.20%
Average Trading Volume: 36,084
Technical Sentiment Signal: Strong Buy
Current Market Cap: £204M
Learn more about MXCT stock on TipRanks’ Stock Analysis page.